SI-BONE Reports Strong Q1 2026 Results with 11.2% Revenue Growth and Reduced Net Loss
SIBN is trading near its 52-week low of $11.48 (13% above the low) on elevated volume (2.7× avg).
Summary
SI-BONE, Inc. delivered strong first-quarter 2026 financial results, reporting an 11.2% increase in revenue and a substantial reduction in net loss, reinforcing its positive trajectory.
Key Events · Earnings and Guidance · SIBN
-
Strong Revenue Growth
Q1 2026 revenue increased 11.2% year-over-year to $52.6 million, driven by higher U.S. procedure volumes and expanded product adoption.
-
Reduced Net Loss
Net loss significantly improved to $4.3 million in Q1 2026, down from $6.5 million in Q1 2025.
-
Improved Operating Cash Flow
Net cash used in operating activities decreased to $2.4 million in Q1 2026 from $4.9 million in the prior year period.
-
Stable Financial Position
The company maintains a strong cash and marketable securities balance of $144.7 million and stable long-term debt of $35.6 million, with compliance across all debt covenants.
Analysis · SIBN · Industrial Applications And Services
SI-BONE, Inc.'s first-quarter 2026 results confirm the positive preliminary announcements, showcasing robust operational performance with revenue growth exceeding expectations and a significant reduction in net loss. The improved cash flow from operations and stable debt position provide a healthy financial runway, reinforcing the company's positive trajectory and strategic execution.
At the time of this filing, SIBN was trading at $13.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $513.7M. The 52-week trading range was $11.48 to $21.89. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.